RGNT (Regentis Biomaterials) Total Current Liabilities: $2.87 Mil (As of Dec. 2025)


RGNT Regentis Biomaterials Ltd RGNT
14 GF Score
Price $3.90
! 2 Warning Signs
View Full Analysis

What is Regentis Biomaterials Total Current Liabilities?

Regentis Biomaterials RGNT -6.02% 14 Total Current Liabilities is $2.87 Mil as of Dec. 2025. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Regentis Biomaterials's total current liabilities for the quarter that ended in Dec. 2025 was $2.87

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Regentis Biomaterials Total Current Liabilities Related Terms

Regentis Biomaterials Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Regentis Biomaterials's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regentis Biomaterials Total Current Liabilities Chart

Regentis Biomaterials Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial 2.72 2.61 3.14 6.49 2.87

Regentis Biomaterials Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 3.14 1.11 6.49 9.71 2.87
RGNT
14GF Score
Regentis Biomaterials Ltd RGNT
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regentis Biomaterials Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Regentis Biomaterials's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.659+1.197
+Other Current Liabilities+Current Deferred Liabilities
=0.018+0
=2.87

Regentis Biomaterials's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.659+1.197
+Other Current Liabilities+Current Deferred Liabilities
=0.018+0
=2.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $2.87 Mil mean?
Regentis Biomaterials (RGNT) has a Total Current Liabilities of $2.87 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Regentis Biomaterials and its competitors.
Is Regentis Biomaterials' Total Current Liabilities too high?
Regentis Biomaterials' current Total Current Liabilities is $2.87 Mil. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' Total Current Liabilities compare to MHUAF and LUCY?
Regentis Biomaterials' Total Current Liabilities of $2.87 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Devices & Instruments company?
A good Total Current Liabilities depends on the Medical Devices & Instruments industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Regentis Biomaterials and its competitors. Regentis Biomaterials's current Total Current Liabilities is $2.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current Total Current Liabilities of $2.87 Mil. The current Total Current Liabilities is $2.87 Mil. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current Total Current Liabilities is $2.87 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regentis Biomaterials Business Description

Address 60, Medinat Hyahudim, Entrance C, Herzlia Pituach, ISR, 4676652
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score

Get the complete analysis for RGNT

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.90
Price